Education & Experience

Research & Publications ажил

• Choi YH, Kim HS, Nam SB, Kang HJ, Na II, Yang SH, Ryoo BY. A Case of Epstein-Barr Virus-positive Diffuse, Large B-cell Lymphoma after Angioimmunoblastic T-cell Lymphoma. Korean J Hematol. 2008 Sep;43(3):174-178
• Choi YH, Kang BW, Hong HS, Kim C, Jang GD, Lee SS, Ryu SK Huh JR, Lee DH, Kim SW, Lee JS, Suh CW. The Role of An Early Interim 18 F-FDG PET/CT for Prediction of Outcomes of Patients with Peripheral T Cell Lymphoma. Blood, Nov 2008; 112: 5272.
• Choi YH, Park KY, Ryoo B, Na II, Yang SH, Koh JS, Kim CH, Lee JC. Presence of Malignant Mesothelial Cells in the Sputum. Intern.Med 2008;47:57-60.
• Sohn B,S., Park I, Kim E,K., Yoon D,H., Lee S,S., Kang B,W., Jang G, Choi Y,H., Kim C, Lee D,H., Kim S, Huh J, Suh C. Comparison of Clinical Outcome After Autologous Stem Cell Transplantation between Patients with Peripheral T-Cell Lymphomas and Diffuse Large B-Cell Lymphoma. Bone Marrow Transplant. 2009;44:287-29311.
• Choi Y,H., Ahn J,H., Kim S, Jung K, Gong G, Kim M, Son B, Ahn S, Kim W,K. Tissue Microarray-Based Study of Patients with Lymph Node-Negative Breast Cancer shows that HER2/neu Overexpression is an Important Predictive Marker of Poor Prognosis. Ann.Oncol. 2009;20:1337-1343.
• Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, et al. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Invest New Drugs. 2010 Aug;28(4):516-522.
• Park KY, Jung JW, Nam SB, Lee HJ, Kim HS, Choi YH, et al. Two lung masses with different responses to pemetrexed. Korean J. Intern. Med. 2010 Jun;25(2):213-216.
• Kim H-R, Kang MS, Na II, Yang SH, Choi YH, Kang HJ, et al. The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients. J. Cancer Res. Clin. Oncol. 2010 Apr;136(4):547-552.
• Noh GY, Hwang D-Y, Choi YH, Lee YY. Effect of diabetes mellitus on outcomes of colorectal cancer. J Korean Soc Coloproctology. 2010 Dec;26(6):424-428.
• Yhim H-Y, Kang HJ,Choi YH, Kim SJ, Kim WS, Chae YS, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer. 2010;10:321.
• Choi YH, Lee JK, Kang HJ, Lee TS, Kim H-R, Kim CH, et al. Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol. 2010 Dec;5(12):1949-1952.
• Choi YH, Kim TW, Lee SS, Hong YS, Ryu M-H, Lee J-L, et al. A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. Cancer Chemother PharmacolCancer Chemother Pharmacol. 2011 Oct;68(4):905-12.
• Kim C, Lee J-L, Choi YH, Kang BW, Ryu M-H, Chang HM, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012 Feb;30(1):306-15
• Choi YH, Kim TW, Kim K-P, Lee SS, Hong YS, Ryu M-H, et al. A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. Oncology. 2012;82(5):290–7.
• Choi YH, Oh SC, Kim JS, Nam S-H, Kim B-S, Cho S-H, et al. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. Cancer Chemother. Pharmacol. 2012 Nov;70(5):665–72.
• Choi YH, Chung J, Na HS. Molecular Methods for Studying the Human Microbiota: Journal of Bacteriology and Virology 2013;43(1):67 – 72
• Na HS, Kim SM, Kim SY, Choi YH, Chung J. The effect of Xylitol on various Oral bacteriaInt J Oral Biol. 2013;38(4):175 - 180.
• Na HS, Kim SY, Choi YH, Lee JY, Chung J. Oral Microbiota Comparison between Healthy volunteers, Periodontitis쟰atients and Oral cancer patients. Int J Oral Biol. 2013;38(4):181 - 188.
• Shin D-Y, Choi YH, Lee H-R, Na II, Yuh YJ, Kim B-S et al. A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site. Cancer Chemother Pharmacol. 2016(1):163-8.